HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Suave 'Beautiful As' Bath & Body Works Claim Deemed Puffery In NAD Review

Executive Summary

Council of Better Business Bureaus Division review Unilever claims for Suave Essentials on challenge by L Brands, which argued “as beautiful as” is linked to a specific product attribute – fragrance – and expressly compares Unilever's products to Bath & Body Works products. L Brands contended “as beautiful as” is equivalent to claim “as appealing as,” which NAD concluded was unsubstantiated in 2016.

You may also be interested in...



Unilever To Appeal NAD Ruling On Suave-Vs-BBW Scent Comparison

The National Advertising Division advises Unilever to discontinue preference and parity claims for Suave body-wash scents, compared with Bath & Body Works fragrances, following an advertising challenge from the latter brand’s parent, L Brands. Unilever intends to appeal the verdict.

California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation

CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.

CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales

Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS139927

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel